.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,802,717

« Back to Dashboard

Claims for Patent: 8,802,717

Title:Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline 1,3-dione
Abstract: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoin- doline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-.alpha. or the inhibition of PDE4.
Inventor(s): Muller; George W. (Rancho Santa Fe, CA), Schafer; Peter H. (Somerset, NJ), Man; Hon-Wah (Princeton, NJ), Ge; Chuansheng (Belle Mead, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:13/682,652
Patent Claims: 1. A method of treating an arthritic condition, which comprises administering to a patient having an arthritic condition a therapeutically effective amount of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetyla- minoisoindoline-1,3-dione.

2. The method of claim 1, wherein the arthritic condition is rheumatoid spondylitis.

3. The method of claim 1, wherein the compound is administered orally.

4. The method of claim 3, wherein about 5 mg to about 500 mg of the compound is administered per day.

5. The method of claim 3, wherein about 10 mg to about 200 mg of the compound is administered per day.

6. The method of claim 3, wherein about 10 mg to about 100 mg of the compound is administered per day.

7. The method of claim 3, wherein the compound is administered twice daily in equally divided doses.

8. The method of claim 3, wherein the stereomerically pure compound comprises greater than about 90% by weight of (+) isomer based on the total weight percent of the compound.

9. The method of claim 3, wherein the stereomerically pure compound comprises greater than about 95% by weight of (+) isomer based on the total weight percent of the compound.

10. The method of claim 3, wherein the stereomerically pure compound comprises greater than about 97% by weight of (+) isomer based on the total weight percent of the compound.

11. The method of claim 3, wherein the compound is administered in capsule form.

12. The method of claim 1, wherein the capsule contains about 10 mg of the compound.

13. The method of claim 11, wherein the capsule contains about 20 mg of the compound.

14. The method of claim 11, wherein the capsule contains about 25 mg of the compound.

15. The method of claim 11, wherein the capsule contains about 50 mg of the compound.

16. The method of claim 1, wherein the compound is administered in tablet form.

17. The method of claim 16, wherein the tablet contains about 10 mg of the compound.

18. The method of claim 16, wherein the tablet contains about 20 mg of the compound.

19. The method of claim 16, wherein the tablet contains about 25 mg of the compound.

20. The method of claim 16, wherein the tablet contains about 50 mg of the compound.

21. A method of treating an arthritic condition, which comprises orally administering to a patient having an arthritic condition about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses.

22. The method of claim 21, wherein the arthritic condition is rheumatoid spondylitis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc